Delivers lower-than-expected sales amid a challenging and volatile consumer and geopolitical environment while maintaining overall market shares and delivering its 10th consecutive quarter of gross margin expansion OAKLAND, Calif., May 5, 2025 — The Clorox Company (NYSE: CLX) today reported results for the third quarter of fiscal year 2025, which ended Mar. 31, 2025. PRESS RELEASE Clorox Reports Q3 Fiscal Year 2025 Results, Updates Outlook Key Segment Results Third-Quarter Fiscal Year 2025 Summary Following ...

Exhibit 99.1 | Press Release | Investor Contact: | | --- | --- | | | Will Gabrielski | | | Senior Vice President, Finance, | | | Treasurer | | | 213.593.8208 | | | William.Gabrielski@aecom.com | Media Contact: Brendan Ranson-Walsh Global Head of Communications 213.996.2367 Brendan.Ranson-Walsh@aecom.com AECOM reports second quarter fiscal 2025 results DALLAS (May 5, 2025) — AECOM (NYSE: ACM), the trusted global infrastructure leader, today reported second quarter fiscal 2025 results. | | | | | | As | | | -- ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (State or other jurisdiction of incorporation or organization) 5619 DTC Parkway, Suite 700 Greenwood Village, Colorado 80111 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______ Commissio ...

Hims & Hers Health, Inc. Reports First Quarter 2025 Financial Results Revenue of $586.0 million, up 111% year-over-year in Q1 2025 Net income of $49.5 million; Adjusted EBITDA of $91.1 million in Q1 2025 Subscribers grew to 2.4 million, up 38% year-over-year in Q1 2025 Af irms full year 2025 revenue guidance of $2.3 billion to $2.4 billion and raises Adjusted EBITDA guidance to a range of $295 million to $335 million Introduces 2030 targets of at least $6.5 billion in revenue and $1.3 billion in Adjusted EB ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) (St ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ FORM 10-Q __________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to Commission File Number 001-37795 _______________________ ...

Revenue Performance - For the three months ended March 31, 2025, net revenue was 100% compared to 100% in the same period of 2024, with total revenue slightly decreasing from 101.5% to 101.4%[129] - Consolidated total revenue increased by $18.3 million, or 6.8%, to $287.4 million for the three months ended March 31, 2025, compared to $269.1 million for the same period in 2024[132] - Consolidated net revenue increased by $18.4 million, or 6.9%, to $283.6 million for the three months ended March 31, 2025, with Executive Search net revenue rising by $11.9 million, or 5.9%[133] - The Americas segment reported net revenue of $144.4 million, an increase of 5.7%, with a 3.6% rise in the number of executive search confirmations[146] - The Europe segment reported net revenue of $45.4 million, an increase of 9.4%, driven by a 7.5% increase in executive search confirmations[150] - The Asia Pacific segment reported net revenue of $23.6 million for the three months ended March 31, 2025, an increase of 1.2% compared to the prior year[154] - The On-Demand Talent segment reported net revenue of $42.6 million for the three months ended March 31, 2025, an increase of 12.4% compared to the prior year[158] - The Heidrick Consulting segment reported net revenue of $27.6 million for the three months ended March 31, 2025, an increase of 6.8% compared to the prior year[163] Operating Expenses and Profitability - Operating expenses increased to 95.6% of net revenue in Q1 2025 from 95.3% in Q1 2024, with salaries and benefits rising to 66.8% from 65.8%[129] - Net income for Q1 2025 was 4.7%, down from 5.3% in Q1 2024, indicating a decline in profitability[129] - Consolidated salaries and benefits expense increased by $15.1 million, or 8.6%, to $189.5 million for the three months ended March 31, 2025[135] - Consolidated general and administrative expenses increased by $0.1 million, or 0.1%, to $41.4 million for the three months ended March 31, 2025[137] - Consolidated cost of services increased by $2.6 million, or 9.6%, to $30.1 million for the three months ended March 31, 2025[139] - Research and development expenses increased by $0.7 million, or 11.8%, to $6.4 million for the three months ended March 31, 2025[141] - The compensation model for consultants ties a portion of their pay to net revenue generated, impacting overall compensation expense and operating margin[127] Key Performance Indicators - Adjusted EBITDA and Adjusted EBITDA margin are key performance indicators, with the potential for improvement as revenue increases without a proportional rise in operating costs[122] - Adjusted EBITDA was $29.1 million for the three months ended March 31, 2025, an increase of $3.3 million, or 12.6%, compared to $25.9 million for the same period in 2024[142] - Adjusted EBITDA margin improved to 10.3% for the three months ended March 31, 2025, compared to 9.8% for the same period in 2024[142] - Adjusted EBITDA for the On-Demand Talent segment improved to $0.4 million for the three months ended March 31, 2025, compared to an Adjusted EBITDA loss of $0.9 million in the prior year[162] - The Global Operations Support segment reported an Adjusted EBITDA loss of $16.9 million for the three months ended March 31, 2025, a decrease of $2.2 million compared to the prior year[170] Strategic Focus and Initiatives - The company is focused on expanding revenue streams beyond executive search through the One Heidrick strategy and the upcoming Heidrick Digital[120] - Heidrick Consulting has pivoted to create new digital solutions for leadership assessments and team acceleration, which can be delivered virtually[119] - The company emphasizes a data-driven approach in executive search, utilizing the Heidrick Leadership Framework and Heidrick Connect for enhanced client engagement[113] - The company employs over 500 consultants globally, leveraging their expertise to enhance leadership effectiveness for clients[110] Risks and Financial Position - The company faces various risks, including macroeconomic conditions, cybersecurity threats, and geopolitical instability, which could materially affect future performance[109] - Cash used in operating activities was $232.2 million for the three months ended March 31, 2025, primarily due to a decrease in accrued expenses of $199.3 million[177] - Cash, cash equivalents, and marketable securities totaled $324.7 million as of March 31, 2025, including $170.6 million held by foreign subsidiaries[176] - The company had no outstanding borrowings as of March 31, 2025, and was in compliance with financial covenants under the Amended Credit Agreement[175] - The company entered into a committed revolving credit facility of $100 million on March 17, 2025, with a maturity date extended to March 17, 2030[173] Currency and Foreign Operations - A 10% change in average exchange rates for foreign currencies could impact net income by approximately $0.6 million for the three months ended March 31, 2025[188] - The company operates in multiple regions including the Americas, Europe, and Asia Pacific, using various currencies[188] - Revenue earned in each country is generally matched with associated expenses, reducing currency risk to earnings[188] - Certain assets and liabilities are denominated in currencies other than the U.S. dollar, leading to potential valuation fluctuations[188] - Local currencies of subsidiaries are generally designated as functional currencies, affecting translation into U.S. dollars[188] - Financial information by segment is detailed in Note 15 of the Quarterly Report on Form 10-Q[188]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40335 Biomea Fusion, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 82-2520134 (State or other jurisdiction ...

Exhibit 99.1 Investor Relations inquiries: News Media inquiries: Justin Schoenberg Keoni Wagner Matson, Inc. Matson, Inc. 510.628.4234 510.628.4534 jschoenberg@matson.com kwagner@matson.com FOR IMMEDIATE RELEASE MATSON, INC. ANNOUNCES FIRST QUARTER 2025 RESULTS HONOLULU, Hawaii (May 5, 2025) – Matson, Inc. ("Matson" or the "Company") (NYSE: MATX), a leading U.S. carrier in the Pacific, today reported net income of $72.3 million, or $2.18 per diluted share, for the quarter ended March 31, 2025. Net income fo ...

Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR inhibitors to treat prostate cancer at the 2025 AACR Annual Meeting Announced clinical trial collaboration and supply agreement with Johnson & Johnson to evaluate ORIC-114 in combination with subcutaneous amivantamab for the first-line treatment of NSCLC patients with EGFR exon 20 insertion mutations Exhibit 99.1 ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates A ...